Comparative Pharmacology
Head-to-head clinical analysis: ORTHO TRI CYCLEN versus ORTHO NOVUM 1 80 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORTHO TRI CYCLEN versus ORTHO NOVUM 1 80 21.
ORTHO TRI-CYCLEN vs ORTHO-NOVUM 1/80 21
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Combined estrogen-progestin oral contraceptive; suppresses gonadotropin release, inhibiting ovulation; increases cervical mucus viscosity and alters endometrial lining.
Combination estrogen-progestin contraceptive. Suppresses gonadotropin (FSH, LH) release from pituitary, inhibiting ovulation. Increases viscosity of cervical mucus, impeding sperm penetration. Induces endometrial thinning, reducing implantation likelihood.
FDA-approved: Prevention of pregnancyOff-label: Treatment of acne vulgaris, management of menstrual disorders
Prevention of pregnancy (FDA-approved)Acne vulgaris (off-label)Dysmenorrhea (off-label)Menstrual irregularities (off-label)
One tablet (norgestimate 0.180-0.215-0.250 mg/ethinyl estradiol 0.035 mg) orally once daily for 21 days, followed by 7 days of placebo or no tablets.
One tablet orally once daily for 21 consecutive days, followed by 7 days off therapy.
None Documented
None Documented
Norethindrone: ~8 hours (terminal). Ethinyl estradiol: ~12-15 hours (terminal). Clinical context: Steady-state achieved within 5-7 days; contraceptive efficacy maintained with daily dosing.
Norethindrone terminal half-life: 8-11 hours; Mestranol (ethinyl estradiol pro-drug) terminal half-life: 10-15 hours (metabolite ethinyl estradiol). Clinical context: Steady-state reached in 5-7 days; once-daily dosing maintains therapeutic levels.
Ethinyl estradiol: primarily metabolized by CYP3A4; norgestimate: rapidly hydrolyzed to norelgestromin (active) then levonorgestrel, metabolized by CYP3A4 and CYP2C9.
Ethinyl estradiol is primarily metabolized via CYP3A4; undergoes first-pass metabolism in gut and liver. Norethindrone is metabolized via reduction and conjugation (glucuronidation).
Norethindrone: 60-80% renal (as metabolites), 20-40% fecal. Ethinyl estradiol: ~40% renal, ~60% fecal. Biliary excretion contributes to fecal elimination.
Renal: ~60% (metabolites, primarily glucuronide and sulfate conjugates), Fecal: ~40% (biliary excretion of metabolites). Unchanged drug negligible.
Norethindrone: ~97% bound to albumin and SHBG. Ethinyl estradiol: ~98% bound to albumin.
Norethindrone: 60-70% bound to SHBG and albumin; Ethinyl estradiol: 95-98% bound to albumin.
Norethindrone: 3-4 L/kg (large distribution into tissues, including breast and reproductive tissues). Ethinyl estradiol: 2-3 L/kg (distributes widely).
Norethindrone: Vd ~4 L/kg (0.9-4 L/kg); Ethinyl estradiol: Vd ~2.7 L/kg. Reflects extensive tissue distribution with accumulation in fat, liver, and reproductive organs.
Norethindrone: ~65% (oral). Ethinyl estradiol: ~40-45% (oral) due to first-pass metabolism.
Oral: Norethindrone ~60-70% (first-pass metabolism); Mestranol undergoes hepatic demethylation to ethinyl estradiol, overall bioavailability of ethinyl estradiol ~40%.
No dose adjustment required for mild to moderate renal impairment. Insufficient data for severe impairment (GFR <30 mL/min); use alternative contraception.
No dose adjustment required for mild to moderate renal impairment. Insufficient data for severe impairment (GFR <30 mL/min); use with caution.
Contraindicated in patients with acute hepatitis, cholestatic jaundice of pregnancy or prior OCP use, or severe cirrhosis (Child-Pugh C). Use with caution in Child-Pugh A/B; dose adjustment not defined but consider lower estrogen options.
Contraindicated in severe hepatic disease (Child-Pugh class C). Use with caution in mild to moderate impairment (Child-Pugh A/B); monitor liver function.
Not indicated in prepubertal children. Postmenarchal adolescents: same dosing as adults. Safety and efficacy not established in children <18 years.
Not indicated for use before menarche. For post-menarchal adolescents, same dosing as adults; no weight-based adjustment required.
Not indicated for use after menopause. No specific geriatric dosing; contraindicated in postmenopausal women.
Not indicated for use after menopause. No specific dose adjustment for older women; consider increased risk of thromboembolic events and cardiovascular disease.
Cigarette smoking increases risk of serious cardiovascular events from combined hormonal contraceptive use. Risk increases with age and number of cigarettes smoked, especially in women over 35.
Cigarette smoking increases risk of serious cardiovascular side effects from combination oral contraceptives. Risk increases with age (especially women over 35) and with heavy smoking (≥15 cigarettes/day). Women using ORTHO-NOVUM should be strongly advised not to smoke.
["Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction)","Hepatic neoplasia (benign/malignant)","Gallbladder disease","Hypertension","Carbohydrate/lipid effects","Hereditary angioedema","Chloasma","Retinal thrombosis","Depression"]
["Increased risk of thromboembolic disorders (MI, stroke, DVT, PE)","Hepatic neoplasia (benign and malignant) reported","Increased risk of gallbladder disease","Elevated blood pressure","Carbohydrate intolerance (monitor diabetic patients)","Ocular lesions (retinal thrombosis, optic neuritis): discontinue if sudden vision loss, proptosis, or diplopia occurs","Depression: discontinue if severe or recurrent","Menstrual irregularities (breakthrough bleeding, amenorrhea)"]
["Thrombophlebitis or thromboembolic disorders","Cerebrovascular or coronary artery disease","Known or suspected breast carcinoma","Undiagnosed abnormal genital bleeding","Pregnancy","Active liver disease or benign/malignant liver tumors","Hypersensitivity to any component","Heavy smoking in women over 35"]
["Thrombophlebitis or thromboembolic disorders (current or history)","Cerebrovascular or coronary artery disease (current or history)","Known or suspected breast carcinoma","Estrogen-dependent neoplasia","Undiagnosed abnormal genital bleeding","Pregnancy (confirmed or suspected)","Benign or malignant liver tumor (current or history)","Known or suspected pregnancy","Hypersensitivity to any component","Cigarette smoking in women over 35"]
Data Pending Review
Data Pending Review
No specific food restrictions. Grapefruit may slightly increase estrogen levels; avoid large amounts. Alcohol consumption may increase hepatic toxicity risk; limit to moderate intake.
No significant food interactions. Grapefruit juice may increase estrogen levels but clinical relevance not established. Avoid St. John's wort as it reduces contraceptive efficacy.
Contraindicated in pregnancy. First trimester: associated with cardiovascular defects and limb reduction defects. Second and third trimesters: no increased risk of major malformations, but may cause fetal harm due to hormonal effects; use only if clearly needed.
First trimester: Increased risk of neural tube defects, cardiovascular anomalies, and oral clefts. Second and third trimesters: Associated with masculinization of female fetuses and potential for other congenital anomalies. Contraindicated in pregnancy.
Small amounts of ethinyl estradiol and norgestimate pass into breast milk; may reduce milk production and composition. M/P ratio not established. Generally avoided during breastfeeding; alternative contraception recommended.
Excreted in breast milk; may reduce milk production and quality. M/P ratio not well established. Use during lactation not recommended.
No dosing adjustments applicable; drug is contraindicated during pregnancy. If used inadvertently, discontinue immediately.
No dose adjustment applicable; drug is contraindicated in pregnancy. If exposure occurs, discontinue immediately and evaluate risks.
Category C
Category C
Contains norgestimate 0.180/0.215/0.250 mg and ethinyl estradiol 0.035 mg. Triphasic regimen mimics natural cycle. Monitor for breakthrough bleeding, especially during first 3 cycles. Use with caution in patients with migraine with aura, hypertension, or history of VTE. Effective for acne vulgaris (FDA-approved indication). Counsel that efficacy may be reduced with concurrent rifampin, certain anticonvulsants, and St. John's wort. Consider switching to monophasic pill if persistent breakthrough bleeding after 3 months.
Contains mestranol (50 mcg) and norethindrone (1 mg). Higher estrogen dose increases thromboembolic risk; contraindicated in smokers >35. Use for contraception only; not for endometriosis due to low progestin. May increase sex hormone-binding globulin.
Take one pill daily at the same time for 21 days, then placebo pills for 7 days.If you miss a pill within 12 hours, take it as soon as remembered. If more than 12 hours late, use backup contraception (e.g., condoms) for 7 days.Do not smoke while taking this medication; smoking increases risk of blood clots and stroke, especially if over 35.Common side effects: spotting between periods, nausea, breast tenderness, headache. These often improve after a few cycles.Seek emergency medical attention for signs of blood clot: leg pain/swelling, sudden chest pain, difficulty breathing, severe headache, vision changes.This medication does not protect against HIV or other sexually transmitted infections.
Take one tablet daily at the same time; if missed, follow package instructions.Smoking increases risk of serious cardiovascular side effects; do not smoke.Use backup contraception if vomiting or diarrhea occurs.Report symptoms of blood clots: leg pain/swelling, chest pain, sudden shortness of breath.This prescription does not protect against HIV or other STDs.